Charles River Laboratories International, Inc. launched Apollo™, an industry-leading, secure, cloud-based platform for drug developers that provides access to study data, study milestones, documents, cost estimates, and program planning tools to save time and enhance the client experience. The platform's current capabilities are designed to support clients with safety assessment and toxicology studies. By providing greater access to study milestones and data, Apollo reduces friction in preclinical studies and contributes to a more efficient and effective process.

Using the cloud-based platform, clients now have access to self-service tools designed to reduce barriers, access the status of studies, data insights and analysis, and download study documents immediately. Additionally, Apollo offers access to a self-service quoting tool, allowing enhanced budget forecasting. Apollo is currently live and available for all ongoing studies.

All Apollo studies provide users the ability to exchange documents, and in vivo general toxicology studies have additional data visualization, program planning and reporting milestone features. Charles River is continuously expanding the scope of enabled features for other study types.